What is the treatment for a patient with hypertriglyceridemia?

Treatment of Elevated Triglycerides

For severe hypertriglyceridemia (≥500 mg/dL), immediately initiate fenofibrate 54-160 mg daily to prevent acute pancreatitis, while for moderate elevations (150-499 mg/dL), prioritize lifestyle modifications and statin therapy if cardiovascular risk is elevated. 1, 2, 3

---

Classification and Risk Stratification

Triglyceride levels determine treatment urgency and approach:

• Normal: <150 mg/dL 2
• Mild-Moderate: 150-499 mg/dL (increased cardiovascular risk) 2, 4
• Severe: 500-999 mg/dL (14% pancreatitis risk) 1, 4
• Very Severe: ≥1,000 mg/dL (high pancreatitis risk, requires emergency intervention) 1, 4

---

Initial Assessment: Identify Secondary Causes FIRST

Before initiating any pharmacotherapy, aggressively evaluate and treat reversible causes: 1, 3

• Uncontrolled diabetes mellitus (most common driver—optimizing glycemic control can reduce triglycerides by 20-50% independent of medications) 1, 2, 4
• Excessive alcohol intake (even 1 ounce daily increases triglycerides 5-10%; complete abstinence mandatory for levels ≥500 mg/dL) 1, 2
• Hypothyroidism (check TSH) 1, 3
• Chronic kidney disease or nephrotic syndrome 1
• Medications: estrogen therapy, thiazide diuretics, beta-blockers, corticosteroids, antiretrovirals 1, 3
• Obesity and metabolic syndrome 2, 5

---

Lifestyle Interventions (Foundation for ALL Patients)

Weight Loss and Exercise

• Target 5-10% body weight reduction (produces 20% triglyceride decrease—the single most effective intervention) 1, 2
• Engage in ≥150 minutes/week of moderate-intensity aerobic activity (reduces triglycerides ~11%) 1, 2

Dietary Modifications by Severity

For Mild-Moderate Hypertriglyceridemia (150-499 mg/dL): 1, 2

• Restrict added sugars to <6% of total daily calories 1, 2
• Limit total fat to 30-35% of calories 1, 2
• Restrict saturated fats to <7% of calories, replace with monounsaturated/polyunsaturated fats 1, 2
• Increase soluble fiber to >10 g/day 1, 2
• Consume ≥2 servings/week of fatty fish (salmon, sardines) 2

For Severe Hypertriglyceridemia (500-999 mg/dL): 1, 4

• Restrict total fat to 20-25% of calories 1, 4
• Completely eliminate all added sugars 1, 4
• Complete alcohol abstinence (mandatory to prevent pancreatitis) 1, 4

For Very Severe Hypertriglyceridemia (≥1,000 mg/dL): 1, 4

• Very low-fat diet: 10-15% of total calories 1, 4
• Eliminate all added sugars and alcohol completely 1, 4
• Consider extreme fat restriction (<5% calories) until levels fall below 1,000 mg/dL 2

---

Pharmacologic Treatment Algorithm

SEVERE TO VERY SEVERE HYPERTRIGLYCERIDEMIA (≥500 mg/dL)

Immediate action required to prevent acute pancreatitis: 1, 4, 3

1. Initiate fenofibrate 54-160 mg daily IMMEDIATELY (first-line therapy, provides 30-50% triglyceride reduction) 1, 4, 3

   • Start at 54 mg daily if mild-moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) 3
   • Contraindicated if eGFR <30 mL/min/1.73 m² 3
   • Adjust dose based on response at 4-8 week intervals 3

2. Do NOT start with statin monotherapy (statins provide only 10-30% triglyceride reduction—insufficient for pancreatitis prevention) 1, 2

3. Once triglycerides fall below 500 mg/dL: 1, 4

   • Reassess LDL-C and cardiovascular risk
   • Add or optimize statin therapy if LDL-C elevated or cardiovascular risk high

4. If triglycerides remain >200 mg/dL after 3 months of fenofibrate + lifestyle optimization: 1, 2

   • Add prescription omega-3 fatty acids (icosapent ethyl 2-4 g/day) as adjunctive therapy

MODERATE HYPERTRIGLYCERIDEMIA (200-499 mg/dL)

Treatment depends on cardiovascular risk and LDL-C levels: 1

If 10-year ASCVD risk ≥7.5% OR established ASCVD OR diabetes: 1

• Initiate moderate-to-high intensity statin therapy (atorvastatin 20-40 mg or rosuvastatin 10-20 mg daily) 1
• Statins provide 10-30% dose-dependent triglyceride reduction plus proven cardiovascular benefit 1
• Target: LDL-C <100 mg/dL (or <70 mg/dL for very high-risk patients) 1, 2
• Secondary target: Non-HDL-C <130 mg/dL 1

If triglycerides remain >200 mg/dL after 3 months of optimized statin + lifestyle: 1, 2

• Add icosapent ethyl 2 g twice daily (if established ASCVD OR diabetes with ≥2 additional cardiovascular risk factors) 1, 2
  • Provides 25% reduction in major adverse cardiovascular events (NNT=21) 1, 2
  • Monitor for increased atrial fibrillation risk 1, 2
• Alternative: Add fenofibrate 54-160 mg daily (if icosapent ethyl criteria not met) 1, 2

MILD HYPERTRIGLYCERIDEMIA (150-199 mg/dL)

Persistently elevated nonfasting triglycerides ≥175 mg/dL are a cardiovascular risk-enhancing factor: 1, 2

• If 10-year ASCVD risk ≥7.5%: Consider moderate-intensity statin therapy 1, 2
• If 10-year ASCVD risk 5-7.5%: Patient-clinician discussion regarding statin initiation 1, 2
• Prioritize aggressive lifestyle modifications for 3 months before pharmacotherapy 1, 2

---

Combination Therapy Safety Considerations

When combining fenofibrate with statins (required for mixed dyslipidemia): 1

• Use lower statin doses to minimize myopathy risk (e.g., atorvastatin 10-20 mg maximum) 1
• Fenofibrate preferred over gemfibrozil (significantly lower myopathy risk when combined with statins) 1, 2
• Monitor creatine kinase levels at baseline and if muscle symptoms develop 1, 2
• Highest risk: Patients >65 years or with renal disease 1

---

Monitoring Strategy

After initiating or adjusting therapy: 1, 2

• Reassess fasting lipid panel in 4-8 weeks 1, 2
• Monitor liver enzymes (AST/ALT) at baseline, 3 months, then annually on fenofibrate 2
• Monitor renal function within 3 months of fenofibrate initiation, then every 6 months 2, 3
• Discontinue fenofibrate if eGFR persistently <30 mL/min/1.73 m² 3

Treatment goals: 1, 2

• Primary: Triglycerides <500 mg/dL (eliminate pancreatitis risk), then <200 mg/dL (ideally <150 mg/dL) 1, 2
• Secondary: Non-HDL-C <130 mg/dL 1
• Withdraw therapy if no adequate response after 2 months at maximum dose (160 mg daily) 3

---

Critical Pitfalls to Avoid

• Never delay fenofibrate in severe hypertriglyceridemia (≥500 mg/dL) while attempting lifestyle modifications alone—pharmacotherapy is mandatory 1, 4
• Never start with statin monotherapy when triglycerides ≥500 mg/dL (insufficient for pancreatitis prevention) 1, 2
• Never combine gemfibrozil with statins (use fenofibrate instead due to lower myopathy risk) 1, 2
• Never ignore secondary causes (especially uncontrolled diabetes—optimizing glucose control can be more effective than additional lipid medications) 1, 2, 4
• Never use over-the-counter fish oil as substitute for prescription omega-3 fatty acids (not equivalent formulations) 2